As plasminogen activator inhibitor-1 (PAI-1), the physiological inhibitor of tissue-type plasminogen activator, is considered to be an important risk factor in several (patho)physiological conditions, many research activities focus on attempts to inhibit this serpin. The approach illustrated in the current study focuses on elucidating important interaction sites allowing the inhibition of PAI-1. Since monoclonal antibodies are in most cases not ideal for therapeutic use, the question of whether smaller molecules exert comparable effects is a hot issue. To answer this question, Cys residues were introduced in PAI-1 at positions previously identified as determining the epitope of a PAI-1-inhibiting antibody, MA-8H9D4, resulting in PAI-1-R300C, PAI-1-Q303C, and PAI-1-D305C. Subsequently, low molecular mass sulfhydryl-specific reagents (i.e. BODIPY® 530/550 IA (molecular mass 626 Da) and BODIPY® FL C 1 -IA (molecular mass 417 Da)) were allowed to react covalently with the cysteine. The functional distribution (inhibitory versus substrate) toward tissue-type plasminogen activator was determined for the labeled and the unlabeled samples. Labeling at position 300 leads to a 1.7-and 2.2-fold increase in SI value for BODIPY® 530/550 IA and BODIPY® FL C 1 -IA, respectively. Labeling at position 303 results in a 3.3-and 1.9-fold increase of the SI value for the large and the small label, respectively. At position 305, the SI values are 3.1-fold increased for both labels. The effect (on SI and on serpin activity) of the manipulations at these positions is in good agreement with the effect exerted by MA-8H9D4. In conclusion, our study provides proof of concept for the proposed approach in evaluating whether targeting a functional epitope with a small synthetic compound may be a feasible strategy in rational drug design.
Plasminogen activator inhibitor-1 (PAI-1) 1 is the most important physiological inhibitor of tissue-type plasminogen activator (t-PA) (1) . It plays an important role in the regulation of the fibrinolytic activity in human blood (2) . The protein contains no cysteines. PAI-1 is a member of the superfamily of the serpins (serine proteinase inhibitors), glycoproteins with a reactive center loop (RCL) comprising the active site (P1-P1Ј residues) that interacts with the proteinase (see Fig. 1 ). Active, inhibitory serpins can inhibit serine proteinases (e.g. t-PA) by a remarkably conformational change-based mechanism in which the proteinase, having initiated cleavage of the scissile bond between P1 and P1Јof the serpin and being covalently linked to the P1 residue, is translocated 70 Å from one pole of the serpin to the other resulting, in a full insertion of the RCL into the body of the serpin (3-6) (see Fig. 1 ).
The kinetics of insertion as well as the length of the RCL play a critical role in this process, as it may affect the required rearrangements within the active site of the proteinase (Scheme 1, P), resulting in an impairment of the enzymatic activity and stabilization of the formed complex (5) (Scheme 1, IP cpx ) (7, 8) . In the absence of a fast distortion of the catalytic triad of the proteinase, the latter remains active and cleaves the bond between its active site and the P1 residue, resulting in a cleaved, inactivated serpin (Scheme 1, I*) and active proteinase. Typically, these two possible pathways are designated inhibitory (k i ) and substrate (k s ) reaction, respectively (Scheme 1). The increase in the fraction of the substrate reaction can be expressed quantitatively by the stoichiometry of inhibition (SI ϭ 1 ϩ k s /k i ), i.e. the number of moles of PAI-1 required for inactivation of one mole of proteinase (9, 10) .
Inhibition of PAI-1, a well established risk factor in cardiovascular diseases, has been the subject of many studies (11) (12) (13) (14) (15) (16) (17) including epitope (16, 18 -20) and paratope analysis (17) of various strongly inhibiting antibodies. Among these, MA-8H9D4 has been shown to interfere with the final locking step in the serpin/proteinase interaction, and the epitope was found to be composed of the amino acids at position 300, 303, and 305 in PAI-1 (see Fig. 1 ) (16) . However, long term in vivo use of monoclonal antibodies is excluded because of their unfavorable pharmacological and immunological properties. Although their putative contribution to rational drug design is well recognized, it is virtually impossible to predict whether a small molecule designed on the paratope/epitope interaction will exert the same inhibiting effect as the corresponding antibody. The current study describes an innovative approach to evaluate at an early stage whether targeting the functional epitope is to be considered. Our strategy, based upon the introduction of a cysteine at the putative target site and a subsequent evaluation of the functional effects of covalently linked Cys labeling reagents, indeed shows that small molecules can exert an effect comparable with that of the corresponding monoclonal antibody. 
EXPERIMENTAL PROCEDURES
DNA Preparation-Mutagenesis was carried out by standard procedures, basically as described before (21) . The presence of the mutation together with the absence of any unwanted mutation was verified by nucleotide sequencing.
Protein Preparation and Purification-Expression and purification of wild-type PAI-1 and PAI-1 variants was performed as described previously, with minor modifications (22, 23) . Purified proteins were subjected to SDS-PAGE for evaluation of their purity, pooled, and stored in aliquots at Ϫ20°C until use. The amount of PAI-1 protein in purified preparations was determined spectrophotometrically at 280 nm (absorbance coefficient A 1 cm 1% ϭ 10). Preparation of Labeled PAI-1 Cysteine Mutants-A PAI-1 cysteine mutant diluted to 0.8 -1.0 mg/ml in phosphate-buffered saline (140 mM NaCl, 2.7 mM KCl, 8 mM Na 2 HPO 4 , 1.5 mM KH 2 PO 4 , pH 7.2) was first incubated with 100 mM dithiothreitol at room temperature for 30 min to activate the thiol group. Then dithiothreitol was removed by gel filtration on a NAP-25 column equilibrated and eluted with phosphatebuffered saline containing 0.1 M Arg/HCl and 5 mM EDTA. Subsequently, the label, either N- (4,4- Fig. 1D )) (Molecular Probes) (stock solution of 5 mg/3.5 ml 100% Me 2 SO), was added immediately to the PAI-1 variant at a 10-fold molar excess. The labeling reaction was performed in the dark for 1 h at room temperature and continued at 4°C for 16 h. After the labeling reaction, the reaction mixture was centrifuged for 15 min at 3500 rpm to remove any precipitated protein.
The excess of BODIPY® was then removed using a NAP-25 column equilibrated and eluted with phosphate-buffered saline, pH 7.2. PAI-1 samples collected before and after labeling were either analyzed directly or stored at Ϫ20°C until use. Wild-type PAI-1 and PAI-1-stab were subjected to a similar treatment and served as a control.
Quantitation and Characterization of the Labeled Protein-The concentration of PAI-1 and the extent of the incorporation of BODIPY® fluorophore were calculated from the absorbances of the fluorophore ( max ϭ 534 and 502 nm for BODIPY® 530/550 IA and BODIPY® FL C 1 -IA, respectively) and PAI-1 ( max ϭ 280 nm) by using the molar absorptivities of 75,400 cm Determination of the Functional Distribution of (Labeled) PAI-1 Variants-PAI-1 samples were diluted with phosphate-buffered saline (140 mM NaCl, 2.7 mM KCl, 8 mM Na 2 HPO 4 , 1.5 mM KH 2 PO 4 , pH 7.2) to a concentration of 150 g/ml and incubated for 25 min at 37°C with t-PA at a 2-fold molar excess. The reaction was terminated by adding SDS (final concentration of 1%) and heating for 30 s at 100°C. Reaction products were analyzed by SDS-PAGE using 10 -15% gradient gels with the Phastsystem TM (Amersham Biosciences). Proteins were visualized by staining with Coomassie Brilliant Blue and quantified by densitometric scanning with the Imagemaster TM (Amersham Biosciences) as described previously (22) .
RESULTS AND DISCUSSION
Based upon the mechanism of inactivation and the position of the epitope of the monoclonal antibody MA-8H9D4, we hypothesized that residues 300, 303, and 305 may represent excellent targetable positions to evaluate the proof of the concept of the newly proposed approach. Therefore, the following mutants were generated in which the respective residue was mutated to a cysteine: PAI-1-R300C, PAI-1-Q303C, and PAI-1-D305C (Fig. 1) .
It should be noted that PAI-1 is distinguished from other serpins by the facile insertion of its RCL, resulting in the spontaneous transformation of the unstable, active form to a stable, inactive latent conformation. This conformational transition is characterized with a half-life of 2.5 h at 37°C (24) . Therefore, the corresponding mutations were also introduced in a functionally stable variant of PAI-1, termed PAI-1-stab, which has a functional half-life of about 150 h (25) . This will allow us to exclude that the observations obtained with wildtype PAI-1 and its respective variants are linked to their ability to convert to the latent form.
After expression and purification, the proteins, including wild-type PAI-1 and PAI-1-stab serving as a control, were treated with either BODIPY® FL C 1 -IA (BDYFLIA, Fig. 1C) or BODIPY® 530/550 IA (BDYIA, Fig. 1D ). After removal of the unbound label, the degree of labeling was determined, revealing 65-100% efficiency for the Cys mutants in wild-type PAI-1 and 100% efficiency for the Cys mutants in PAI-1-stab. Wildtype PAI-1 and PAI-1-stab, not containing any cysteines, showed less then 10% of labeling as expected, confirming a sulfhydryl-specific labeling reaction. The functional distribution (i.e. percentage of active, latent and cleavable PAI-1) and the corresponding SI value were then determined toward its natural target t-PA.
Replacement of the amino acids involved in the epitope of MA-8H9D4 (Arg-300, Gln-303, and Asp-305) by a cysteine may have a small but significant effect on the SI value as compared with that of wild-type PAI-1 (WT PAI-1, SI ϭ 1.3 Ϯ 0.0) ( Table  I) PAI-1-stab) . The observation that mere substitution by a Cys residue affects the functional distribution of PAI-1 is in line with the hypothesis that this region plays an important role in the final step of the serpin/proteinase complex ( Fig. 1) (5, 16, 26 ). Cys-specific labeling of the constructed variants resulted in an increase in cleaved material concomitant with a decrease in stable complex formation (Fig. 2) . Whereas for wild-type PAI-1 (subjected to the labeling procedure), the SI value remains virtually unchanged (p Ͼ 0.05 for both labels), a significant increase can be seen for the labeled mutants (Table 1A) . Labeling at position 300 leads to a 1.7-fold increase in SI value for BDYIA and a 2.2-fold increase for BDYFLIA (p Ͻ 0.001 versus WT PAI-1). Labeling at position 303 increases the ratio 3.3-1.9-fold (p Ͻ 0.05 versus WT PAI-1). Labeling at position 305 increases the ratio 3.1-fold for both labels (p Ͻ 0.05 versus WT PAI-1). Strikingly, the effect of Cys introduction and subsequent labeling on the SI values is comparable with the effect induced by the monoclonal antibody or its scFv derivative under comparable experimental conditions (Table I) (14, 27, 28) and corresponds to a 50 -70% reduction in serpin inhibitory activity.
TABLE I SI values of the different PAI-1 variants
Since active PAI-1 converts spontaneously to latent PAI-1, leading to a smaller amount of protein that can undergo interference with the label, the same approach was applied in a stable variant, PAI-1-stab. Overall, the results obtained with this stable variant reinforce the observations obtained with the variants in wild-type PAI-1 ( Fig. 2 and Table I ). Whereas for PAI-1-stab, the SI value remains unchanged (SI ϭ 1.6 -1.7, p Ͼ 0.05), labeling at position 300 leads to a 1.6-fold increase in SI value for BDYIA (p Ͻ 0.0001 versus PAI-1-stab) and a 1.1-fold increase for BDYFLIA (p Ͻ 0.01 versus PAI-1-stab). Labeling at position 303 increases the ratio 2.2-1.3-fold (p Ͻ 0.001 versus PAI-1-stab). Labeling at position 305 increases the ratio 4.9-fold for BDYIA (p Ͻ 0.0001 versus PAI-1-stab) and 2.0-fold for BDYFLIA (p Ͻ 0.00001 versus PAI-1-stab). From these results, it is clear that the larger label (BDYIA) exerts a more dramatic effect on the SI value, indicating that the efficiency of an inhibitor targeted to this region is clearly size-dependent (Table I and Fig. 2 ). The highest SI value is seen for PAI-1-stab-D305C labeled with BDYIA, corresponding to an 84% reduction in activity in comparison with PAI-1-stab. As observed in wildtype PAI-1, these effects are comparable with those induced by the monoclonal antibody.
Taken together, our data clearly demonstrate that the method described here can be used to test whether development of small compounds, targeted to the epitope of an inhibitory monoclonal antibody, may eventually result in a successful inhibition of the functional properties of the antigen. If the Cys labeling-based screening reveals that the labels used exert an effect comparable with that observed for the corresponding antibody, it is meaningful to look for peptides or peptidomimetics, e.g. based on the paratope of the antibody, with a similar size as the labels. The labels used in this study have a molecular mass of 626 and 417 Da, corresponding to the size of a pentapeptide and tri-or tetrapeptide, respectively. The design and optimization of such peptides/peptidomimetics may ultimately lead to low molecular weight compounds that possess the selectivity of the antibody but have superior pharmacological and pharmacokinetic properties.
